Tanya Sandrock and Alexander Kamb Pages 395 - 404 ( 10 )
Genomics and proteomics have unveiled a plethora of protein-protein interactions that may control cellular processes involved in disease development. Many of these interactions involve non-traditional candidate targets (i.e., neither enzymes nor cell surface receptors / channels). To date, non-traditional targets have largely been ignored by the pharmaceutical industry or have failed to lead to drugs. This review focuses on the use of transdominant genetically encoded agents and specialized small-molecule drugs to explore this void.
transdominant genetics, reverse genetics, protein-protein interaction, non-traditional drug target
Novartis Institutes for BioMedical Research, Inc., 400 Technology Sq., Cambridge, MA 02139, USA.